The PhINEST study - Pharyngeal ICU Novel Electrical Stimulation Therapy Study protocol of a prospective, multi-site, randomized, sham-controlled, single-blind (outcome assessor-blinded) study by Schefold, Joerg C. et al.
D
ow
nloaded
from
https://journals.lw
w
.com
/m
d-journalby
B
hD
M
f5eP
H
K
av1zE
oum
1tQ
fN
4a+kJLhE
ZgbsIH
o4X
M
i0hC
yw
C
X
1A
W
nY
Q
p/IlQ
rH
D
3O
tLR
A
X
G
V
rQ
qX
Y
1vkpxqd3X
Z/H
R
X
w
uM
C
m
Y
gjB
f0A
29jA
=
on
05/26/2020
Downloadedfromhttps://journals.lww.com/md-journalbyBhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo4XMi0hCywCX1AWnYQp/IlQrHD3OtLRAXGVrQqXY1vkpxqd3XZ/HRXwuMCmYgjBf0A29jA=on05/26/2020
The PhINEST study – Pharyngeal ICU Novel
Electrical Stimulation Therapy
Study protocol of a prospective, multi-site, randomized,
sham-controlled, single-blind (outcome assessor-blinded) study
Joerg C. Schefold, MDa,
∗
, Minna Bäcklund, MDb, Tero Ala-Kokko, MD, PhDc, Patrick Zuercher, MDa,
Rajat Mukherjee, PhDd, Satish Mistry, PhDe, Stephan A. Mayer, MDf, Rainer Dziewas, MD, PhDg,
Jan Bakker, MD, PhDh, Stephan M. Jakob, MD, PhDa
Abstract
Introduction: Post-extubation dysphagia is commonly observed in ICU patients and associated with increased
aspiration rates, delayed resumption of oral intake/ malnutrition, prolonged ICU and hospital length of stay, decreased
quality of life, and increasedmortality. Conventional therapeutic approaches are limited. Pharyngeal electrical stimulation (PES)
was previously shown to improve swallowing function and airway safety in severely dysphagic tracheostomised stroke
patients.
Methods: In a multi-center, single-blind, 1:1 randomized controlled study, up to 400 (360 evaluable) mixed emergency
adult ICU patients with recent extubation following mechanical ventilation and confirmed oropharyngeal dysphagia will be
enrolled at investigational academic ICUs. Primary objective is to evaluate the effectiveness of PES in reducing the severity of unsafe
swallows. Patients will be randomized to receive PES (or sham) treatment on 3 consecutive days in addition to best supportive care.
Primary endpoint is a composite of 2 endpoints with hierarchy based on clinical priorities:
Current list of participating sites: Helsinki University Hospital, Oulu University Hospital, Bern University Hospital. Recruitment status (as of the 17th December 2019): 19
patients have consented to participate in PhINEST. Study duration: The trial is expected to run for 48 months (last patient last visit expected in April 2023).
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1) Swallowing safety based on worst penetration-aspiration-scale (PAS) score in series of up to 4 boli using thin stimuli approx. From
24 to 60hours after treatment completion, converted to a trichotomized ordinal response of safe (PAS 1–3), penetration (PAS 4–5),
or aspiration (PAS 6–8).
2) Dysphagia Outcome and Severity Scale scores determined by bedside assessment 7±1 days after treatment completion.
Oropharyngeal dysphagia will be assessed by Fiberoptic Endoscopic Evaluation of Swallowing by blinded study staff. Patients will
be followed-up for a maximum of 90 days.
Discussion: This study will evaluate the effects of PES on swallowing safety in critically ill ICU patients post mechanical ventilation
with oropharyngeal dysphagia.
Abbreviations: AE = adverse event, CI = confidence interval, DMC = data monitoring committee, DOSS = dysphagia outcome
and severity scale, EC = ethics committee, eCRF = electronic case report forms, EDC = electronic data capture, FEES = fiberoptic
endoscopic evaluation of swallowing, FOIS= functional oral intake scale, GDS= global dysphagia severity rating scale, HCP= health
care professional, ICF = informed consent form, ICU = intensive care unit, IDDSI = International Dysphagia Diet Standardization
Initiative Scale, IFRC = Independent FEES Review Committee, ITT = intent-to-treat, LOS = length of stay, MM = medical monitor,
PAS = penetration aspiration scale, PEG = percutaneous endoscopic gastrostomy, PES = pharyngeal electrical stimulation, PI =
principal investigator, PP = per protocol, RASS = richmond agitation and sedation scale, SLP/T = speech language pathologist/
therapist, SOC = standard of care, SSR = sample size re-estimation, SSS = murray secretion severity rating scale, TISS-28 =
therapeutic intervention scoring system-28, YRS = Yale pharyngeal residue severity rating scale.
Keywords: FEES, intensive care unit, mechanical ventilation, oropharyngeal dysphagia, PES, pharyngeal electrical stimulation
1. Introduction
Oropharyngeal dysphagia, also referred to as dysphagia or
“disordered swallowing”, is an abnormality of the swallow
physiology (reviewed in[1]). It is observed frequently in patients
with stroke[2] and additional neurological conditions, head and/or
neck cancer,[3] cervical spine surgery,[4] prolonged intubation,[5,6]
tracheostomy,[7,8] and/or mechanical ventilation.[9] Although the
literature reports a high incidence of dysphagia following
endotracheal intubation for more than 48hours, the reported
incidence rate varies widely from to 3% to 83%.[5,10,11] Studies
have also shown that prolonged intubation might be a risk factor
for dysphagia,[12,13] as artificial airways increase the risk of upper
airway injury and concomitant laryngeal pathologies.[14–16]
However, causes for “ICU-acquired” dysphagia are multifactorial
and with many risk factors still currently unknown.[1]
Recently, the incidence rates of post-extubation dysphagia in a
large cohort of 933 mixed medical and surgical ICU patients was
reported by us in the DYnAMICS study.[9] We revealed the
significance of post-extubation dysphagia in the ICU with 12.4%
(n=116/933) of the total ICUpopulation (18.3%of emergency and
4.9% of elective ICU patients) affected. Moreover, 60% of patients
leaving the ICU having been identified as dysphagia positive, were
still dysphagic at hospital discharge. Furthermore, the presence of
dysphagia was associated with increased morbidity (e.g., increased
resourceuse, increasedhospital lengthof stay) and, after adjustment,
dysphagia remained an independent predictor for 28-day and 90-
day mortality (excess 90-day mortality 9.2%).[9] Diagnosis of post-
extubation dysphagia is most commonly established by ICU nurses
at the bedside (dysphagia screening) followed by an assessment by a
trained speech and language pathologist (SLP) or occupational/
physio-therapist.[1,17,18] Fiberoptic Endoscopic Evaluation of Swal-
lowing (FEES) is an instrumental examination technique that allows
visualization of the pharynx during swallowing. Data show that
FEES is well tolerated and considered a safe technique[19–22] with
minimal complications.[23]
Treatment for dysphagia is typically limited to dietary adjustment
andpostural changesaswell as compensatorymanoeuvres aiming to
improve swallowing function.[1,17,24] The therapeutic efficiency of
such ‘traditional’ therapies is limited, with no evidence for clinical
benefit in ICUpatients.[1,25]Novel interventional approaches to treat
dysphagiaare thereforewarranted. Pharyngeal electrical stimulation
(PES) is a novel technique that offers a new treatment option for
dysphagic patients and in 2 recent studies, the benefits of PES in
severely dysphagic tracheotomized stroke patients[26,27] were
demonstrated. In the first study, Suntrup et al[27] conducted a
single-center, randomized controlled pilot study in 30 severely
dysphagic tracheotomized acute stroke patients. Patients were given
PES or sham and thereafter assessed for decannulation readiness
using a FEES-based decannulation algorithm.[28] In their study,
Suntrup et al[27] found that dysphagia improved enabling
decannulation in 15/20 (75%) patients of the treatment group,
whereas only 2/10 (20%) of control patients showed spontaneous
remission of post-stroke dysphagia sufficient enough to allow for
subsequent removal of the tracheal cannula. In the follow-on multi-
center, randomized controlled PHAST-TRAC study by Dziewas
et al[26] conducted in 69 severely dysphagic tracheotomized stroke,
PES was associated with 17/35 (49%) patients being ready for
tracheostomy decannulation when compared to just 3/34 (3%)
controls. PES is considered to stimulate afferent sensory feedback
resulting in enhanced reorganization of the swallow-related motor-
cortex, faciliatory activation of cortico-bulbar pathways, and
increased salivary substance P levels, a swallow-related neurotrans-
mitter, inducingmore quantitative and qualitative swallows.[1,29–31]
Moreover, the relationshipbetweenPES treatment efficacyandshort
times to treatment (favoring treatment earlier after stroke, or with a
shorter duration of mechanical ventilation) in the PHAST-TRAC
study[26] are thought to be related to the development of critical
illness dysphagia due to critical illness polyneuropathy and
myopathy inpatientswithprolonged ICU treatment andmechanical
ventilation.
We embarked to design a clinical study that evaluates the
effectiveness of PES in reducing the severity of unsafe swallows in
mixed emergency adult ICU patients with recent extubation
following mechanical ventilation.
2. Objectives
2.1. Primary objective
To evaluate the effectiveness of PES (Phagenyx) treatment in
reducing the severity of unsafe swallows.
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2.2. Secondary objectives
 To evaluate and further characterize the effectiveness of PES
treatment in improving nutritional management and reducing
the severity of dysphagia.
 To evaluate the effectiveness of PES treatment on general
patient health outcomes.
2.3. Other objectives and supplementary data collected
Exploratory additional analysis of the effectiveness of PES
treatment in reducing dysphagia severity and other health
outcome measures.
3. Methods
3.1. Design
Prospective, multi-center, 1:1 randomized, sham-controlled,
patient-masked, outcome assessor-blinded study designed to
assess the effects of PES for the treatment of oropharyngeal
dysphagia after invasive mechanical ventilation (of any length of
time; by means of naso- or oro-tracheal tube) in critically ill
intensive care unit (ICU) patients (active study protocol version
1.0, dated Nov 8, 2018). A study flowchart is provided (Fig. 1).
Patient randomization will occur after dysphagia severity is
classified as ‘aspiration’ (PAS score ≥ 6) on FEES assessment, and
the Phagenyx Catheter is successfully placed. Randomization will
be on a 1:1 basis at each site stratified for neurological vs non-
neurological reason for admission (APACHE IV diagnostic
group). All randomized patients will receive either PES treatment
or sham (comparator) by a health care professional who is
unblinded to the treatment assignment (PES treater). Sham
treatment will be performed using the same device without
delivering energy. Administration of all protocol-specific assess-
ments, other than PES or sham, will be conducted by study
personnel who are blinded to the treatment assignment, including
therapists delivering standard dysphagia care (other forms of
electrical stimulation treatment for dysphagia are not permitted
in this study). FEES assessments of swallowing safety and
decisions on patient treatment will be made by the local clinical
team responsible for the patient’s care. Study data will be
collected using an electronic Case Report Form (eCRF)
(SYNCRONY, Syntactx Technologies LLC, NY).
An Independent FEES Review Committee (IFRC), external to
the study sites, will be established for analysis of all study-related
FEES assessment parameters and to confirm/validate the PAS
scoring of the local clinical FEES assessor(s). FEES results will not
be scored in duplicate but discrepancies in ratings between the
local team and IFRC, or concerns about the quality of submitted
records will be reviewed and discussed with the local team for (re-
)training purposes only. All FEES records will be coded so that
records are only identified by site number, bolus number, patient
number, and study visit (i.e., screening or follow-up). The IFRC
will be blinded to the treatment assignment as well as the actual
treatment received.
Six or more investigational academic hospital sites across
Europe are anticipated to participate in this study. Factors
considered for site qualification of ICUs include, but are not
limited to: potential number of suitable patients, availability, and
experience of conducting FEES. The enrolment period is expected
to be approximately 48 months from the time of first patient
recruitment to the final study visit. Each patient’s participation
will last for up to 90 days with assessments at the following
intervals: screening, baseline, day 2 (approx. 24–60hours), 7±1
days, 14±1 days or hospital discharge (whichever is first) after
completion of the final PES treatment. 30-day and 90-day
mortality data will also be collected from the patients (electronic
health record) medical notes - this will not require an additional
visit but a phone call may be conducted depending on the
patient’s status. Dysphagic patients enrolled into the study will
continue to receive nutrition as deemed appropriate by the ICU
team. Patients with a nasogastric feeding tube in place at the time
of screening/enrolment will have their nasogastric tube replaced
with the Phagenyx Catheter since the Phagenyx Catheter may
also be used to deliver nutrition to the patient as required for up
to 30 days after placement.
4. Study population
Up to 400 (360 evaluable) mixed emergency (unplanned)
admission adult critically ill ICU patients post invasive
mechanical ventilation with confirmed oropharyngeal dysphagia
will be recruited in to this study.
5. Inclusion and exclusion criteria
Pre-screening inclusion criteria (all of the following criteria must
apply):
 Age ≥18 and 85 years,
 Emergency ICU admission (unplanned admission),
 Recent extubation following invasive mechanical ventilation
(of any duration) by means of endotracheal tube,
 Presence of post-extubation dysphagia as determined by the
participating sites’ standard of care (SOC).
Screening / Enrolment Criteria: To be eligible for enrolment in
this study, an individual must meet all of the following additional
criteria:
 Presence of written informed consent according to respective
national guidelines (patients are considered enrolled once
informed consent is provided),
 Dysphagia severity status classified according to PAS on FEES
assessment as ‘aspiration’ (PAS score ≥6),
 Richmond Agitation and Sedation Scale (RASS) score within
the range of1 to +2 (i.e., if score equals2,3,4 or +3, +4,
patient is excluded),
Randomization inclusion criteria (post consent): The following
additional criteria must be met for randomization:
 Successful placement and subjective tolerance of the Phagenyx
Catheter within 2 days of extubation.
Exclusion criteria: (any of the following):
 Nasal anatomical deformity, nasal airway obstruction; patient
who have had recent oral, nasal or oesophageal surgery or
patient presenting with facial and/or cranial fractures or any
other circumstance (e.g., history of oesophageal perforation,
stricture, pouch, resection or rupture) where placement of a
standard nasogastric feeding tube would be deemed unsafe,
 Cardiac or respiratory condition that might render the
insertion (placement) of a catheter into the throat unsafe,
 Presence of a permanently implanted electrical device
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 Are pregnant (pregnancy test) or known lactating women,
 Have non-neurogenic dysphagia (e.g., Cancer-related),
 Any prior tracheostomy,
 Patients who at the time of extubation have a treatment
limitation, life expectancy, or are moribund, that prevents or
would prevent compliance with study-specific instructions or
procedures (as judged by the investigator)
 Severe cognitive impairment or other reasons that prevents
compliance with study-specific instructions or procedures (as
judged by the investigator),
Figure 1. Study flowchart.
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 Previous history of dysphagia of any origin,
 Pre-existing tube feeding of any form (e.g., percutaneous
gastric/enteral feeding tube related to previous injuries
indicating previous dysphagia. Nasogastric feeding tubes are
not an exclusion criterion),
 Participation in another interventional study (medicinal or
device) that could influence the outcomes of PES,
 Treatment of dysphagia with other forms of electrical
stimulation.
6. Outcome measures
6.1. Primary endpoint
A composite endpoint using the Finkelstein-Schoenfeld (FS)[32]
(win-ratio) statistic, (see statistical considerations) analyzed on a
hierarchy, based on clinical priorities, of the following
2 endpoints:
 Swallowing safety based on worst PAS score in a series of up to
4 boli
o using thin stimuli (water) for each patient as determined by a
FEES assessment on day 2 (approx. 24–60hours) after
completion of the final PES treatment, converted to a
trichotomized ordinal response of safe (PAS 1–3), penetra-
tion (PAS 4–5), or aspiration (PAS 6–8),
 Dysphagia Outcome and Severity Scale (DOSS) score deter-
mined by bedside assessment 7±1 days after completion of the
final PES treatment.
6.2. Secondary endpoints
1. Changes in nutritional management and severity of dysphagia
will be assessed by:
 Dysphagia status as measured by DOSS at baseline, day 2
(approx. 24–60hours), 7±1 days and at 14±1 days (or
hospital discharge if earlier) after completion of the final
PES treatment (to assess changes in functional severity of
dysphagia over time),
 Time (days) from randomization to removal of feeding tube,
 Time (days) to first oral intake (if applicable. Oral intake is
minimally defined as movement from for example FOIS 3
(Tube dependent with consistent intake of liquid or food) to
FOIS 4 (Total oral diet of a single consistency) or fromDOSS
2 (Moderately severe dysphagia) to DOSS 3 (Moderate
dysphagia),
 Total days of enteral feeding,
 FOIS scale at baseline, day 2 (approx. 24–60hours), 7±1
days and at 14±1 days (or hospital discharge if earlier) after
completion of the final PES treatment.
 General health outcomes will be assessed by:
 Time (days) from extubation to ICU discharge,
 ICU LOS (Length of stay in ICU),
 Hospital LOS (Length of stay in hospital)
 Number of patients with re-intubation during hospital stay
 Mortality.
6.3. Other endpoints and supplementary data collected
Additional data for exploratory analysis will be collected in
relation to dysphagia severity and general patient outcomes. For
changes in severity of dysphagia between FEES assessments, the
IFRC will evaluate secretion severity (Murray Secretion Severity
Rating Scale (SSS)), bolus residue (Yale Pharyngeal Residue
SeverityRating Scale (YRS)) and global dysphagia severity (Global
Dysphagia severity Score (GDS). Further, swallowing safety and
efficiencywill be analyzed using theworst PAS score for each bolus
consistency for eachpatient asdeterminedbyaFEESassessmenton
day 2 (approx. 24–60hours) after completion of final PES
treatment, converted to a dichotomized ordinal response of
non-aspirator (PAS 1–5) or aspirator (PAS 6–8) (performed to
address presence of aspiration, a key medical problem). General
patient health outcome data collected and to be analyzed include
time from extubation to hospital discharge (days), days on
antimicrobials post-extubation (while in ICU), hospital discharge
destination (home, home + care, nursing home, other hospital,
rehabilitation center), ICU readmission rate during hospital stay,
number of and reason for tracheostomies per group after PES
treatment during hospital stay and total number of chest X-rays
during hospital stay after ICU discharge for suspected pneumonia.
Phagenyx treatment parameters (catheter insertion-related, ease of
use, threshold, tolerance and stimulation levels) and nursing
workload (TISS-28) data will also be collected.
7. Study intervention and comparator
For the study intervention (active PES) and sham (comparator), a
commercial device (Phagenyx, Phagenesis Ltd, Manchester, UK),
which comprises a nasogastric feeding catheter housing stimulation
ring-electrodes, and a computerized base station that delivers
stimulation in the range 1 to 50mA at 5Hz will be used. All eligible
patients will undergo PES catheter placement. Appropriate adjust-
ment and placement of the PES catheter in each patient is ensured
using catheter markings, aspirate test or X-ray, and fixation of the
catheter using a securing clamp. Catheter ease of use will be
documented in the eCRF. PES treatment (active) and sham
(comparator) will be delivered for 10 minutes per day (as per the
device’s programming and CE) for 3 consecutive days[33,34] after
randomization and performed by a health care professional (nurse,
therapist, or physician) unblinded to treatment assignment (PES
treater). Sham treatment will be performed using the same device
without delivering any energy. To deliver (active) PES, the current
intensity (mA) at which PES-treatment will be delivered is
individually adjusted and optimized at the start of each treatment
session by the PES treater in response to patient responses. This
treatment optimization procedure involves increasing the current
intensity incrementally from1mA to detect the perceptual threshold
(PT – patient first aware of stimulation) and then to a maximum
tolerated threshold (MTT – patient no longer wants current
increased further) intensity levels three times each respectively.
Thereafter, the optimal treatment intensity is automatically
calculated by the base station using the average values of the three
trials according to the formula PT + 0.75  (MTT  PT).[26,35]
To deliver sham PES, the optimization procedure is imitated
exactly as in (active) PES to mitigate any bias or effect of time
spent interacting with the patient during (active) PES, however,
no current is applied. Treatment parameters will be documented
in the eCRF.
8. Randomization
Patients will be randomly allocated to PES treatment or sham
(comparator) according to a permutated block randomization
Schefold et al. Medicine (2020) 99:11 www.md-journal.com
5
stratified by site and reason for ICU admission (neurological vs
non-neurological according to APACHE IV diagnostic criteria)
using a random mixture of blocks of size 2 and 4. The
randomization ratio will be 1:1. The PES treater(s) at site shall not
be blinded to the patient’s randomization assignment in order to
be able to deliver PES treatment or sham (comparator).
Randomization assignment will be via the web-based study
EDC with access restricted to authorized PES treaters. The
randomization page of the EDC will only become available once
the patient is confirmed to have met all of the inclusion/exclusion
criteria and the treatment catheter is successfully placed and
tolerated.
9. Procedures for emergency unblinding
In the event of a medical emergency which requires identification
of an individual patient’s randomization and (PES or sham)
treatment information, investigators will be able to access this
information via the PES treater(s). Reasons for unblinding will be
documented in the patient’s medical records.
10. Study assessments
10.1. Screening and baseline assessments
Informed consent will be obtained at the screening visit, by the
local principal investigator (or designee) from the patient or their
legal representative according to respective local/national guide-
lines using approved consent forms (study flowchart Fig. 1). A
SPIRIT figure is provided (Fig. 2).
In addition to the assessments detailed below, a medical
history, demographic data and the patient’s current medical
status will be recorded at the baseline visit. Medical history and
demographic data will be obtained from the patient’s medical
record. Other information captured will include: functional
severity data (e.g., APACHE II, SAPS II), BMI, RASS, nursing
workload (TISS-28), standard of care dysphagia care and feeding
/ nutrition being provided to the patient, ET tube and
tracheostomy status. Information obtained from these assess-
ments will be recorded in the eCRF.
10.2. Fiberoptic endoscopic evaluation of swallowing
(FEES)
FEES is recognized, validated, and routinely used in many
hospitals across Europe for instrumental dysphagia assessment. It
is considered a gold standard technique for airway- and swallow-
safety[19–22] assessment and is the recommended methodology in
current guidelines.[20,36] Complications such as discomfort,
gagging, vomiting, vaso-vagal syncope, anterior or posterior
epistaxis or rare complications such as laryngospasm are
expected to occur in<1% of examinations.[23] In this study,
FEES will be performed via nasal induction of an endoscope into
the pharynx with visualization of the larynx (details are given
elsewhere [1]). FEES assessments will be conducted at screening
and on day 2 (approx. 24–60hours) after completion of the final
PES treatment. The FEES assessment will capture:
 1  30 second video prior to any boli stimuli to assess
secretions severity.
 4  10ml swallow trials with thin liquid (water, International
Dysphagia Diet Standardisation Initiative (IDDSI [37]) level 0)
stimuli.
 2  10ml swallow trials with semi-solid (puree, IDDSI level 4)
stimuli.
 2 non-obligatory soft and bite-sized swallow trials with solid
(white bread without the crust approximately 1.5cm  1.5cm
 0.5cm, IDDSI level 6) stimuli presented only to patients in
whom no residues are observed on thin liquid and puree
swallow trials.
Data will be entered in the eCRF. Coded video records will also
be provided to the IFRC for further analysis and validation of
local PAS scores for the thin liquid stimuli (for (re)training
purposes only). IFRC members will score videos blinded to the
site and other member’s scores to allow unbiased scoring. FEES
results will not be scored in duplicate, PAS ratings by the local site
investigator will be used for all primary endpoint analyses and
clinical decision-making.
10.3. FEES stopping criteria
If gross aspiration (PAS ≥6, see below) of two consecutive bolus
trials of the same consistency are observed, that consistency
should be stopped and the investigator administering the FEES
(or trained and authorized designee) should decide either to move
to the next consistency (to assess any potential dietary
modification) or terminate the FEES. A ‘Stop’ may be applied
at any time if the investigator administering the FEES (or trained
and authorized designee) feels it to be unsafe for the patient to
continue.
11. Assessment scoring scales
11.1. Penetration aspiration scale score (incl. definitions):
The PAS is a validated 8-point ordinal scale that quantifies
penetration and aspiration events observed during instrumental
swallow assessment.[38] The scale ranges from 1 (normal
swallow: material does not enter airway) to 8 (severe aspiration:
material enters the airway, passes below the vocal folds & no
effort is made to eject). Swallowing severity will be assessed using
the PAS observed during FEES at screening and on day 2 (approx.
24–60hours) after completion of the final PES treatment. The
worst PAS score for each thin liquid bolus will be recorded in the
eCRF. IFRC PAS scores will be entered in a separate portion of
the eCRF.
11.2. Functional oral intake scale (FOIS)
The FOIS was developed to document the functional level of oral
intake of food and liquid in stroke patients with dysphagia.[39] It
is a 7-point ordinal scale easily completed by clinicians based on
information contained in medical charts, dietary journals, and/or
patient reports. Verification of patient reports may be obtained
by a spouse or family members or from a variety of sources for
institutionalized patients. The score ranges from 1 (nothing by
mouth) to 7 (total oral diet with no restriction). FOIS scores will
be recorded in the eCRF at the screening, day 2, 7±1 days and
14±1 days visits.
11.3. Dysphagia outcome and severity scale (DOSS)
The DOSS is a simple, easy-to-use, 7-point scale developed to
systematically rate the functional severity of dysphagia based on
objective assessment and make recommendations for diet level,
independence level, and type of nutrition.[40] The score ranges
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from 1 (severe dysphagia) to 7 (normal in all situations). DOSS
scores will be recorded in the eCRF at the screening, day 2, 7±1
days and 14±1 days visits.
11.4. Murray secretion severity rating scale (SSS)
The SSS is a simple, easy-to-use, 4-point scale developed to
systematically rate the graduation of accumulated secretions
within the pharyngolarynx and trachea during an objective
assessment using FEES[41] by trained clinicians. The score ranges
from 0 (normal) to 3 (severe). Secretion severity will be assessed
by the IFRC using the SSS observed during FEES at screening and
on day 2 (approx. 24–60hours) after completion of the final PES
treatment. SSS scores will be recorded in the eCRF.
11.5. Yale pharyngeal residue severity rating scale (YRS)
The Yale Pharyngeal Residue Severity Rating Scale (YRS) is a
reliable, validated, anatomically defined, and image-based five-
point ordinal rating scale to determine severity of post-swallow
pharyngeal residue location (vallecula and pyriform sinus) and
amount (none, trace, mild, moderate, and severe) during
FEES.[42] Residue severity will be assessed by the IFRC using
the YRS observed during FEES at screening and on day 2
(approx. 24–60hours) after completion of the final PES
treatment. YRS scores will be recorded in the eCRF.
11.6. Global dysphagia severity rating scale (GDS)
The Global Dysphagia Severity ratings scale (GDS) is a simple,
easy-to-use, 4-point scale developed to systematically rate the
severity of dysphagia during an objective assessment using
FEES[43] by trained clinicians. Dysphagia severity will be assessed
by the IFRC using the GDS observed during FEES at screening
and on day 2 (approx. 24–60hours) after completion of the final
PES treatment. GDS scores will be recorded in the eCRF.
12. Data collection, management, and
confidentiality
Study data will be collected and stored in a validated, password
protected electronic data capture (EDC) system using eCRFs.
Designated site personnel will be trained to enter data into the
web-based, study-specific EDC system. The EDC system allows
for tracking of all data elements and any changes made (full audit
trail).
As per ISO14155: 2011 (section 6.3, 6.7), in order to assure
appropriate conduct of the study, participating investigators and/
or institutions shall provide direct access to source data during and
after the clinical investigation for monitoring, audits, EC review
and regulatory inspections. Patient confidentiality will be strictly
held in trust by the investigators, study staff, the sponsor(s) and
their agents to the extent allowed by law, including Personally
Identifiable Information. Investigators will ensure protection of
Figure 2. SPIRIT Figure.
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patient personal data and that all reports, publications, and any
other disclosures, except where required by law are identified only
by the patient identification number and site identification number
tomaintain patient confidentiality. All patient study recordswill be
kept safely in an access-controlled area. At the end of the study, all
records will continue to be kept in a secure location for at least 15
years (or per local regulations) after the study is closed.
13. Clinical monitoring, quality assurance and
quality control
Clinical site monitoring will be conducted to help ensure that the
rights and well-being of patients are protected, that the reported
study data are accurate, complete, verifiable and that the conduct
of the study is compliant with the currently approved protocol/
amendment(s) and with applicable regulatory requirement(s)
including ISO14155: 2011 and ICH GCPs. The sponsor or
designee Clinical Research Organization (SyntactxEU Limited)
will train all Investigators and relevant study staff at or prior to
site initiation and monitor the study throughout its duration.
Study monitors will visit each site at appropriate intervals to
review clinical data for accuracy and completeness and to help
ensure compliance with the protocol. A study termination (close-
out) monitoring visit will be conducted at the completion of the
study. A Monitoring Plan is established to outline roles and
responsibilities.
14. Study governance
Phagenesis Ltd is the study Sponsor and has the overall
responsibility for the conduct and safety of the study. The
sponsor is responsible for assuring that the study meets the
regulatory requirements of applicable competent authorities and
governing institutional review boards/ethics committees. A Trial
Steering Committee is established and is responsible for general
oversight of the study. This committee will meet periodically to
monitor clinical site progress and protocol compliance. The
committee will be responsible for reviewing the final results.
Clinical trial liability insurance is provided by the Sponsor for all
study participants in accordance with applicable laws and
regulations of the countries where the trial will be conducted to
provide financial compensation in case of harm by study
measures, if that should occur.
15. Safety oversight
AMedical Monitor (MM), in conjunction with the sponsor, will
review adverse events (AE) of interest listings and will flag any
events that require further review/investigation or if a safety
reviewmeeting is required. TheMM is independent of Phagenesis
and any study site. The MM’s roles and responsibilities are
outlined in a Safety Management Plan. An independent Data
Monitoring Committee (DMC) will be established for the
purposes of this study. The DMC will be responsible for
monitoring aggregate safety information and the impact of AEs
of interest on the safety and well-being of the patients,
particularly if events relate to the Phagenyx system and study
procedures. Safety and efficacy will be checked at the interim
analysis. The DMC may recommend that the sponsor modify or
stop the study based on safety information, or for efficacy/
futility. At the planned Interim Analysis, the DMCwill also make
recommendations on all pre-specified decision rules for study
termination, continuation or adaption (e.g., Sample Size Re-
estimation and/or population enrichment). The DMC members
will be independent of Phagenesis Ltd and any participating study
site. The DMC’s roles and responsibilities will be outlined in a
DMC Charter.
16. Protocol amendment(s)
Any revision/amendment(s) to the Protocol or Informed Consent
documents will be submitted to applicable local/national ethics
committees/institutional review boards in accordance with
applicable regulations. Approvals will be obtained prior to
implementing Protocol revisions at the sites.
17. Statistical considerations
17.1. Statistical hypotheses
The primary effectiveness analysis (Finkelstein-Schoenfeld
(FS)[32] (win-ratio) statistic) is on the composite of two endpoints
in the following hierarchy based on clinical priorities:
1. Swallowing safety based onworst PAS score in series of up to 4
boli using thin stimuli (water) for each patient as determined
by a FEES assessment on day 2 (approx. 24–60hours) after
completion of the final PES treatment, converted to a
trichotomized ordinal response of safe (PAS 1–3), penetration
(PAS 4–5), or aspiration (PAS 6–8).
2. DOSS score determined by bedside assessment 7±1 days after
completion of the final PES treatment.
Using the FS approach, each treatment arm patient will be
compared to each control arm patient and a winner/loser
determined. Comparisons are made hierarchically as defined
above so that if the treatment arm patient performs better than
the control arm patient with respect to the first hierarchy level
(PAS) outcome then the treatment arm patient gets a score of +1
(winner) otherwise a score of 1 (loser) is assigned. If the first
hierarchy level comparison is tied then the comparison is done
with respect to the second outcome (DOSS) and the same scoring
procedure is followed. The FS-statistic is based on the mean of the
scores obtained from all such comparisons. If P is the probability
that a randomly picked treatment arm patient performs better
than a randomly picked control arm patient, then the expected
value of the FS-statistic is given by 2 (P – 0.5). The hypothesis of
interest is a one-sided null: H0: P .5 vs the one-sided alternative
H1: P> .5. PAS and DOSS scores are ordinal outcomes. For each
pair of patients evaluated (a pair being composed of one treated
patient and one control patient), a binary outcome is derived that
indicates whether the treated patient or the control patient
performs better.
17.2. Sample size determination
Sample size calculations were carried out using simulations and
are adjusted for interim analysis. Assuming that 50% of control
patients will move from PAS score of 6–8 at baseline to a PAS
score of 1–5 post-intervention and the corresponding number of
patients in the PES treatment group is 65% (15% effect-size) and
that the PES treatment group will benefit with a mean increase of
0.7 points on the DOSS score, 100 patients per arm will be
required to achieve a power of at least 90%. Thus Nplanned=200
is the minimum sample size (unless the study is stopped early for
futility at the only interim analysis). To allow for adaptations in
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design with respect to sample size and population enrichment, a
maximum (evaluable) sample of Nmax=360 is pre-specified. To
account for a 10% lost-to-follow-up, a maximum of 400 patients
will be recruited.
17.3. Population for analyses
 The Intent to Treat (ITT) Population will consist of all patients
that were randomised, irrespective of their protocol adherence
and continued participation in the study.
 The Per Protocol (PP) Population will consist of all randomised
patients who completed the full PES or Sham treatment
regimen according to their randomisation assignment and for
whom the composite primary endpoint data are available.
 The Safety Population will consist of all patients that were
enrolled in the study and underwent the screening FEES with or
without subsequent placement of the PES Catheter.
17.4. Statistical analyses
Tabulations will be produced for appropriate demographic,
baseline, effectiveness and safety parameters. For categorical
variables, summary tabulations of the number and percentage
within each category (with a category for missing data) of the
parameter will be presented. For continuous variables, the mean,
median, standard deviation, minimum and maximum values will
be presented. Time to event data will be summarized using
Kaplan–Meier methodology using 25th, 50th (median), and 75th
percentiles with associated 2-sided 95% confidence intervals, as
well as percent of censored observations. Formal statistical
hypothesis testing will be conducted at the 1-sided, 0.025 level of
significance. A Statistical Analysis Plan (SAP) will detail all
statistical analyses planned for this study and will be established
prior to the planned Interim Analysis.
18. Discussion
This study evaluates the effectiveness of PES treatment in
reducing severity of unsafe swallowing in recently extubated ICU
patients with oropharyngeal dysphagia.
Post-extubation ICU-acquired dysphagia represents a major
therapeutic challenge without evidence-based treatment.[44] PES
stimulates afferent sensory feedback for the responsible motor-
cortex, activates cortico-bulbar pathways, and increases swal-
low-related neurotransmitter concentration, all contributing to
improved swallowing.[1,29–31] Safety data on the use of PES in
acute stroke patients has been provided.[35] The PHAST-TRAC
study[26] demonstrated that PES improved swallowing in
dysphagic tracheotomized stroke patients, enabling earlier
decannulation compared to controls. Moreover, pre-publication
data from the PHADER registry[45] showed improved swallow-
ing and shorter length of hospital stay in 50 ICU patients with
neurogenic dysphagia treated with PES. Therefore, previous trials
have focused mainly on patients after stroke, with outcomes
related to removal or avoidance of tracheostomy. In contrast, the
present trial includes a general population of critically ill patients,
and will answer whether PES reduces severity of unsafe
swallowing. The strengths of this trail are its size, measurements
of multiple dysphagia scores, and the inclusion of a general ICU
population. The following limitations to this study seem
apparent. First, although most dysphagia scales are validated,
they may be considered somewhat subjective to interpretation,
however, all investigators are trained on the correct interpreta-
tion prior to study start. Second, some of the exclusion criteria
may theoretically overlap or could be perceived as not mutually
exclusive. Third, inclusion of patients might be limited by the
required expertise needed for FEES and PES, especially during
weekends. Fourth, some could consider the fact that PhINEST is
an industry-sponsored trial as a limitation, however, adequate
blinding of the Sponsor (blinded) and all respective site staff (e.g.,
FEES and other assessment investigators (blinded) vs PES treaters
(unblinded)) is ensured, and all authors of the paper will have full
access to the data at the end of the trial.
In conclusion, this trial will answer the question, whether PES
can reduce dysphagia severity in a general ICU population with
oropharyngeal dysphagia after extubation.
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